Development of an ambulatory infusion protocol for Abatacept
Abstract
The identification of the genetic causes of Common Variable Immune Deficiency (CVID) has led to recognition of the need for biological medications to treat the autoimmune manifestations that CVID patients with LRBA and CTLA4 deficiency experience. Immunologists have not traditionally used biological medications as treatment in CVID patients and may not be familiar with the use of them. We present the process and protocol as well as a nursing checklist used by the Division of Rheumatology for the use of Abatacept.
Statement of novelty: The methodology used to develop the order set and nursing checklist may be applied to other biologic medications as they become available.
Formats available
You can view the full content in the following formats:
REFERENCES
Bristol-Myers Squibb. 2006. Orencia (abatacept), PRODUCT MONOGRAPH Intravenous Infusion, 250 mg/15 mL vial Solution for Subcutaneous Injection, 125 mg/mL Selective Co-stimulation Modulator. Retrieved from https://www.bms.com.
Consolaro A., Negro G., Lanni S., Martini A., and Ravelli A. 2012. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 30: S157–S162.
Lo B., Zhang K., Lu W., Zheng L., Zhang Q., Kanellopoulou C., Zhang Y., Liu Z., Fritz J.M., Marsh R., Husami A., Kissell D., Nortman S., Chaturvedi V., Haines H., Young L.R., Mo J., Filipovich A.H., Bleesing J.J., Mustillo P., Stephens M., Rueda C.M., Chougnet C.A., Hoebe K., McElwee J., Hughes J.D., Karakoe-Aydiner E., Matthews K.F., Price S., Su H.C., Koneti Rao V., Lenardo M.J., and Jordan M.B. 2015. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 349(6246): 436–440.
Ministry of Health and Long-Term Care Exceptional Access Program (EAP). 2017. EAP reimbursement criteria for frequently requested drugs. Queen’s Printer for Ontario 2009-2010. Last modified 2017-12-21.
Resnick E.S., Moshier E.L., Godbold J.H., and Cunningham-Rundles C. 2012. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 119(7): 1650–1657.
Vital E.M. and Emery P. 2006. Abatacept in the treatment of rheumatoid arthritis. Ther. Clin. Risk Manag. 2(4): 365–375.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 5 • Number 2 • June 2018
Pages: 61 - 65
History
Received: 5 April 2018
Accepted: 8 May 2018
Accepted manuscript online: 14 May 2018
Copyright
© 2018.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
KarenQueffelec, MichelleAnderson, HollyConvery, and BrendaReid. 2018. Development of an ambulatory infusion protocol for Abatacept. LymphoSign Journal.
5(2): 61-65. https://doi.org/10.14785/lymphosign-2018-0005
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Login options
Check if you access through your login credentials or your institution to get full access on this article.
